| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.3 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.032 | 0.3 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.3 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.3 |